| | | | | | | | | | |
|
|
| Dockets Entered
On January 10, 2008
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1980N-0314
|
| Sodium/Potassium Content of Food Include in Food Labeling
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| 2004N-0217
|
| Nutrient content claims: DHA, EPA, and ALA (Omega-3 Fatty Acids)
|
|
|
| 2006D-0063
|
| Draft Guidance for Industry and Food and Drug Administration; The Review and Inspection of Premarket Approval Applications under the Bioresearch Monitoring Program; Availability
|
|
|
| 2006D-0228
|
| Guidance for Industry and Food and Drug Administration Staff; The Review and Inspection of Premarket Approval Applications under the Bioresearch Monitoring Program
|
|
|
| 2007D-0364
|
| Impact-Resistant Lenses: Questions and Answers Guidance
|
|
|
| 2007D-0463
|
| Revised Compliance Policy Guide Sec. 575.100 Pesticide Chemical Residues in Food and Feed Enforcement Criteria (CPG 7141.01)
|
|
|
| 2007D-0491
|
| Guidance for Industry: Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act
|
|
|
| 2007D-0492
|
| Guidance for Industry and Food and Drug Administration; Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements
|
|
|
|
| 2007N-0462
|
| Compliance Policy Guide Sec. 555.700 Revocation of Tolerances for Cancelled Pesticides (CPG 7120.29); Withdrawal
|
|
|
| 2007P-0295
|
| Make a determination that Inderal (Propranolol Hydrochloride Tablets, 10 mg and 20 mg, NDA 016418, Product Numbers 001 and 003 respectively) held by Wyeth Pharmaceuticals, Inc., were not discontinued
|
|
|
|
|
|
| 2007P-0320
|
| Regulation or Guideline to Label Medical Devices that Leach DEHP Plasticizers
|
|
|
| 2007P-0457
|
| Mandatory Use of Non-Animal Methods in the Development and Approval of Drugs and Devices
|
|
|
| 1980N-0314
|
| Sodium/Potassium Content of Food Include in Food Labeling
|
|
|
| ANS 531
|
| FDA / HFE88 to Mrs. Newbauer
|
| Vol #:
|
| 13
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| LET 21318
|
| Natural Organics, Inc.
|
| Vol #:
|
| 183
|
|
|
| LET 21319
|
| Natural Organics, Inc.
|
| Vol #:
|
| 183
|
|
|
| LET 21320
|
| Natural Organics, Inc.
|
| Vol #:
|
| 193
|
|
|
| LET 21321
|
| Natural Organics, Inc.
|
| Vol #:
|
| 183
|
|
|
| LET 21322
|
| Natural Organics, Inc.
|
| Vol #:
|
| 183
|
|
|
| LET 21323
|
| DreamQuest Nutraceuticals
|
| Vol #:
|
| 183
|
|
|
| 2004N-0217
|
| Nutrient content claims: DHA, EPA, and ALA (Omega-3 Fatty Acids)
|
|
|
| EC 1
|
| Mr. David Hernick
|
| Vol #:
|
| 3
|
|
|
| 2006D-0063
|
| Draft Guidance for Industry and Food and Drug Administration; The Review and Inspection of Premarket Approval Applications under the Bioresearch Monitoring Program; Availability
|
|
|
|
|
|
|
| GDL 2
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
| NAD 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2006D-0228
|
| Guidance for Industry and Food and Drug Administration Staff; The Review and Inspection of Premarket Approval Applications under the Bioresearch Monitoring Program
|
|
|
| GDL 2
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
| NAD 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2007D-0364
|
| Impact-Resistant Lenses: Questions and Answers Guidance
|
|
| | | | | | | | |
|
|
| EC 22
|
| Mr. James Pagano
|
| Vol #:
|
| 1
|
|
|
| EC 23
|
| OAA,POF,ELOA,EOA,
|
| Vol #:
|
| 1
|
|
|
| EC 24
|
| Mr. Timothy Hoffpauir
|
| Vol #:
|
| 1
|
|
|
| 2007D-0463
|
| Revised Compliance Policy Guide Sec. 575.100 Pesticide Chemical Residues in Food and Feed Enforcement Criteria (CPG 7141.01)
|
|
|
| GDL 1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
| NAD 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2007D-0491
|
| Guidance for Industry: Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act
|
|
|
|
| |
|
| EC 1
|
| Dr. Chad Lewis
|
| Vol #:
|
| 1
|
|
|
| 2007D-0492
|
| Guidance for Industry and Food and Drug Administration; Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements
|
|
|
|
|
|
|
| EC 6
|
| None
|
| Vol #:
|
| 1
|
|
|
| EC 7
|
| Dolle Communications
|
| Vol #:
|
| 1
|
|
|
| 2007N-0462
|
| Compliance Policy Guide Sec. 555.700 Revocation of Tolerances for Cancelled Pesticides (CPG 7120.29); Withdrawal
|
|
|
| N 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2007P-0295
|
| Make a determination that Inderal (Propranolol Hydrochloride Tablets, 10 mg and 20 mg, NDA 016418, Product Numbers 001 and 003 respectively) held by Wyeth Pharmaceuticals, Inc., were not discontinued
|
|
|
|
|
|
|
| N 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2007P-0320
|
| Regulation or Guideline to Label Medical Devices that Leach DEHP Plasticizers
|
|
|
| EC 23
|
| Ms. Lisa Hartmayer
|
| Vol #:
|
| 1
|
|
|
| EC 24
|
| UCSF
|
| Vol #:
|
| 1
|
|
|
| 2007P-0457
|
| Mandatory Use of Non-Animal Methods in the Development and Approval of Drugs and Devices
|
|
|
| EC 4
|
| Ms. Dawn Gurley
|
| Vol #:
|
| 1
|
|